BeOne Medicines Ltd. — Director's Dealing 2024

Dec 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BeiGene, Ltd. (BGNE)
CIK: 0001651308
Period of Report: 2024-12-14

Reporting Person: OYLER JOHN (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-12-14	Ordinary Shares	M	1300000	$0.50	Acquired	2978833	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-12-14	Share Option (Right to Buy)	$0.50	M	1300000	Disposed	2025-07-19	Ordinary Shares (1300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	481533	Indirect
Ordinary Shares	7727927	Indirect
Ordinary Shares	28204115	Indirect
Ordinary Shares	9545000	Indirect
Ordinary Shares	102188	Indirect

Footnotes

F1: The Reporting Person exercised and held these option shares.

F2: These securities are held by the P&O Trust, the beneficiaries of which include the Reporting Person's child and others, for which the Reporting Person disclaims beneficial ownership.

F3: These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F4: These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

F5: These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.

F6: These securities are held by The John Oyler Legacy Trust for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.

F7: These securities vest over a five-year period as follows: 20% on July 19, 2016, and the remaining in 48 successive equal monthly installments, subject to continued service.